{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T22:28:25Z","timestamp":1759962505815},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,4,10]],"date-time":"2010-04-10T00:00:00Z","timestamp":1270857600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s10067-010-1410-x","type":"journal-article","created":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T04:43:42Z","timestamp":1270788222000},"page":"677-681","source":"Crossref","is-referenced-by-count":14,"title":["Serious musculoskeletal infections in children receiving anti-tumor necrosis factor-\u03b1 therapy: a case series"],"prefix":"10.1007","volume":"29","author":[{"given":"Kimberly","family":"Morishita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Petty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Bolaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Turvey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,10]]},"reference":[{"key":"1410_CR1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/00148581-200406030-00001","volume":"6","author":"R Carrasco","year":"2004","unstructured":"Carrasco R, Smith JA, Lovell D (2004) Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. Paediatr Drugs 6:137\u2013146","journal-title":"Paediatr Drugs"},{"key":"1410_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/sarh.2003.50022","volume":"33","author":"DG Stokes","year":"2003","unstructured":"Stokes DG, Kremer JM (2003) Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 33:1\u201318","journal-title":"Semin Arthritis Rheum"},{"key":"1410_CR3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S1473-3099(03)00545-0","volume":"3","author":"MA Gardam","year":"2003","unstructured":"Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148\u2013155","journal-title":"Lancet Infect Dis"},{"key":"1410_CR4","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.berh.2006.08.010","volume":"20","author":"A Strangfeld","year":"2006","unstructured":"Strangfeld A, Listing J (2006) Infection and musculoskeletal conditions: bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol 20:1181\u20131195","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1410_CR5","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","volume":"38","author":"RS Wallis","year":"2004","unstructured":"Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261\u20131265","journal-title":"Clin Infect Dis"},{"key":"1410_CR6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K et al (2008) Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 359:810\u2013820","journal-title":"N Engl J Med"},{"key":"1410_CR7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, Giannini EH, Reiff A, Cawkwell GD, Silverman ED, Nocton JJ et al (2000) Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 342:763\u2013769","journal-title":"N Engl J Med"},{"key":"1410_CR8","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"N Ruperto","year":"2007","unstructured":"Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G et al (2007) A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 56:3096\u20133106","journal-title":"Arthritis Rheum"},{"key":"1410_CR9","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295:2275\u20132285","journal-title":"JAMA"},{"key":"1410_CR10","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.md.0000180044.19285.9a","volume":"84","author":"NF Crum","year":"2005","unstructured":"Crum NF, Lederman ER, Wallace MR (2005) Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84:291\u2013302","journal-title":"Medicine (Baltimore)"},{"key":"1410_CR11","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","volume":"48","author":"JJ Gomez-Reino","year":"2003","unstructured":"Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122\u20132127","journal-title":"Arthritis Rheum"},{"key":"1410_CR12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/rheumatology\/keg263","volume":"42","author":"S Kroesen","year":"2003","unstructured":"Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 42:617\u2013621","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"1410_CR13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00040-08","volume":"22","author":"EM Salvana","year":"2009","unstructured":"Salvana EM, Salata RA (2009) Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 22(2):274\u201390","journal-title":"Clin Microbiol Rev"},{"key":"1410_CR14","first-page":"286","volume":"22","author":"RL Elwood","year":"2003","unstructured":"Elwood RL, Pelszynski MM, Corman LI (2003) Multifocal septic arthritis and osteomyelitis caused by group A Streptococcus in a patient receiving immunomodulating therapy with etanercept. Pediatr Infect Dis J 22:286\u2013288","journal-title":"Pediatr Infect Dis J"},{"key":"1410_CR15","first-page":"2563","volume":"30","author":"DE Furst","year":"2003","unstructured":"Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D et al (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30:2563\u20132571","journal-title":"J Rheumatol"},{"key":"1410_CR16","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594\u20131602","journal-title":"N Engl J Med"},{"key":"1410_CR17","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2003.009563","volume":"62","author":"LB Putte van de","year":"2003","unstructured":"van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL et al (2003) Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12-week, phase II study. Ann Rheum Dis 62:1168\u20131177","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1410_CR18","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","volume":"68","author":"JP Leombruno","year":"2008","unstructured":"Leombruno JP, Einarson TR, Keystone EC (2008) The safety of anti-Tumor Necrosis Factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events. Ann Rheum Dis 68(7):1136\u20131145","journal-title":"Ann Rheum Dis"},{"key":"1410_CR19","first-page":"825","volume":"33","author":"PG Fitch","year":"2006","unstructured":"Fitch PG, Cron RQ (2006) Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha. J Rheumatol 33:825, author reply 826\u20137","journal-title":"J Rheumatol"},{"key":"1410_CR20","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/rheumatology\/keg378","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Balint PV, Wood F, Sturrock RD (2003) Early diagnosis of pyomyositis using clinic-based ultrasonography in a patient receiving infliximab therapy for Behcet's disease. Rheumatology (Oxford) 42:1564\u20131565","journal-title":"Rheumatology (Oxford)"},{"key":"1410_CR21","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1164\/rccm.200206-563OC","volume":"167","author":"KL Wood","year":"2003","unstructured":"Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB et al (2003) Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 167:1279\u20131282","journal-title":"Am J Respir Crit Care Med"},{"key":"1410_CR22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa011858","volume":"346","author":"A Myers","year":"2002","unstructured":"Myers A, Clark J, Foster H (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623\u2013626","journal-title":"N Engl J Med"},{"key":"1410_CR23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/rheumatology\/keh074","volume":"43","author":"W Armbrust","year":"2004","unstructured":"Armbrust W, Kamphuis SS, Wolfs TW, Fiselier TJ, Nikkels PG, Kuis W et al (2004) Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 43:527\u2013529","journal-title":"Rheumatology (Oxford)"},{"key":"1410_CR24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/rheumatology\/kep148","volume":"48","author":"D Eleftheriou","year":"2009","unstructured":"Eleftheriou D, Melo M, Marks SD, Tullus K, Sills J, Cleary G et al (2009) Biologic therapy in primary systemic vasculitis of the young. Rheumatology (Oxford) 48:978\u2013986","journal-title":"Rheumatology (Oxford)"},{"key":"1410_CR25","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","volume":"48","author":"DJ Lovell","year":"2003","unstructured":"Lovell DJ, Giannini EH, Reiff A, Jones OY, Schneider R, Olson JC et al (2003) Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 48:218\u2013226","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1410_CR26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","volume":"68","author":"G Horneff","year":"2009","unstructured":"Horneff G, De Bock F, Foeldvari I, Girschick HJ, Michels H, Moebius D et al (2009) Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 68(4):519\u2013525","journal-title":"Ann Rheum Dis"},{"key":"1410_CR27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00003086-200401000-00037","volume":"418","author":"ST Sauer","year":"2004","unstructured":"Sauer ST, Farrell E, Geller E, Pizzutillo PD (2004) Septic arthritis in a patient with juvenile rheumatoid arthritis. Clin Orthop Relat Res 418:219\u2013221","journal-title":"Clin Orthop Relat Res"},{"key":"1410_CR28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/000992289903800807","volume":"38","author":"HM Feder Jr","year":"1999","unstructured":"Feder HM Jr, Lawrence C (1999) Group A streptococcal multifocal septic arthritis: a case report. Clin Pediatr (Phila) 38:481\u2013483","journal-title":"Clin Pediatr (Phila)"},{"key":"1410_CR29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1542\/peds.50.3.437","volume":"50","author":"JD Nelson","year":"1972","unstructured":"Nelson JD (1972) The bacterial etiology and antibiotic management of septic arthritis in infants and children. Pediatrics 50:437\u2013440","journal-title":"Pediatrics"},{"key":"1410_CR30","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/01241398-199607000-00021","volume":"16","author":"WJ Mills","year":"1996","unstructured":"Mills WJ, Mosca VS, Nizet V (1996) Orthopaedic manifestations of invasive group A streptococcal infections complicating primary varicella. J Pediatr Orthop 16:522\u2013528","journal-title":"J Pediatr Orthop"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1410-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-010-1410-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-010-1410-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T19:05:47Z","timestamp":1685559947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-010-1410-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,10]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1007\/s10067-010-1410-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,10]]}}}